Clinical Partnerships
Let’s work together to improve
cancer care for patients everywhere
cancer care for patients everywhere
Since its inception, Perthera has worked with a wide range of organizations to advance cancer care for patients through Perthera’s precision Oncology capabilities. If you would like Perthera to assist you and your organization through a business partnership, we’re here to help.
The Perthera Report can be a powerful tool for advocacy organizations by providing patients and their physicians with ranked therapy options that match their multi-omic tumor profile. Importantly, the Perthera Report creates a nexus around which patients, physicians, researchers, and advocacy groups can all collaborate in their efforts to improve therapy results for any tumor type.
- Perthera has documented improved outcomes when matched therapies are available and used by the doctor for the patient.
- Increased opportunities for clinical trial participation.
- Ability to track outcomes and capture, structure, and curate data for research purposes.
Previous
Next
Perthera’s extensive Precision Oncology capabilities can assist Biopharma companies in many areas such as Perthera’s Real World Evidence database, clinical trial matching, and advanced data analytics.
Enhance Your R&D with Real-World Evidence Data
By partnering with Perthera, you can gain a distinct advantage in the Oncology market with our powerful Precision Oncology Platform.
We provide customized solutions revolving around these capabilities:
- Real World Evidence database, directly linked to our Biorepository.
- Screening and optimizing clinical trial enrollment.
- Prospective and retrospective analysis to capture program-specific insights at the patient level.
- Obtain patient consents and longitudinally track clinical and treatment outcomes.
- Precision Oncology Platform, which has been shown to significantly improve patient OS & PFS outcomes in patients with pancreatic cancer when utilizing our matched therapy options – as demonstrated in our recent publication in The Lancet Oncology.
- Post-market surveillance.
We provide customized solutions revolving around these capabilities:
- Real World Evidence database, directly linked to our Biorepository.
- Screening and optimizing clinical trial enrollment.
- Prospective and retrospective analysis to capture program-specific insights at the patient level.
- Obtain patient consents and longitudinally track clinical and treatment outcomes.
- Precision Oncology Platform, which has been shown to significantly improve patient OS & PFS outcomes in patients with pancreatic cancer when utilizing our matched therapy options – as demonstrated in our recent publication in The Lancet Oncology.
- Post-market surveillance.
Advance Your Precision Oncology Efforts & Market Share
Perthera is not a Lab. We do partner with Labs to increase utilization of NGS testing.
Perthera delivers a Precision Oncology Platform designed to match patients to the right therapy for their unique cancer. Combining a lab’s powerful testing capabilities with Perthera’s Platform can optimize lab services, increase the Lab’s access to Oncologists, and drive increased market share.
Our Platform features our Therapeutic Intelligence Engine, Virtual Molecular Tumor Board, and ranked therapy options. This Platform can be applied seamlessly to testing for advanced stage cancer patients.
- Enhanced analysis
- Therapeutic Intelligence Engine
- Commercialize new assays
- Variant interpretation
- Outcomes captured
- Sales & marketing support
Perthera’s Precision Oncology Platform’s capabilities can assist CROs with clinical studies using utilizing Perthera’s Real World Evidence database, therapy matching, and advanced data analytics.
Advancing Your Trial Enrollment at No Cost
The Perthera Precision Oncology Platform and Perthera Report have been used by clinicians across the
nation for 10 years. We are always looking to partner with leading CROs to strengthen their clinical trial services.
Our Perthera Report has been utilized by over 250 cancer clinicians, providing us with the ability to complement the efforts of CROs by increasing their enrollment of specific patients through coordination of multi-omic molecular profiling. With a limited to no cost pilot program, we can demonstrate our capabilities, innovative strategies, and show how we deliver results.
- Accelerate clinical trial enrollment.
- Screening using Patient Coordinators.
- Resource and control groups for post-market surveillance.
- Low cost capture of Real World Evidence.
Perthera’s Precision Oncology Platform can assist payers in getting their patients more rapidly on the most cost effective therapies with the greatest chance of success. By limiting expensive futility treatments sooner, payers can ultimately improve both clinical outcomes and the value of therapy.
Contact Perthera and let us show you how you can better serve your members and, in doing so, better serve your bottom line. Precision cancer therapies and clinical trials can bring cutting edge care to your members while helping to control costs. Our Perthera Data Analytics can provide the evidence you need to increase both the quality and the efficiency of the cancer care you are providing. Contact us to discuss how Perthera can help you help your members.
